NUPROBE

Company Overview

NuProbe Inc. is developing NGS-based liquid biopsy technologies for noninvasive detection of rare genetic variants relating to cancer, NIPT and infectious disease screening applications.

NuProbe’s platform blocker displacement amplification (BDA) technology allows for ultra-low-frequency variant detection over a high-multiplex set of genomic targets using very little sequencing depth.

The company’s products include Varmap NSCLC NGS panel (detects more than 1,100 mutations in COSMIC database) and Varmap Melanoma NGS panel (detects more than 370 mutations). These tests are offered for research use only.

In January 2020, NuProbe and CarrierGene Biotech Co. Ltd. (Suzhou, China) completed a merger and integration. CarrierGene is an expert in infertility gene testing in the field of reproductive health and brings this capability to the merger.

Also, in January 2020, NuProbe partnered with Illumina to develop NGS-based clinical molecular diagnostic tests for genetic disorders.

In June 2020, NuProbe partnered with the Weigao Group to develop an NGS-based liquid biopsy panel for NSCLC using its blocker displacement amplification technology.

In March 2020, NuProbe formed a partnership with Qiagen to develop NGS-based cancer liquid biopsy tests. The companies agreed to integrate their respective technologies, NuProbe’s BDA and Qiagen’s single primer extension technology. The combined platform would be used to analyze DNA mutations with low variant allele fractions.

In April 2023, Agena Bioscience and nRichDX announced the progression of their prior technical collaboration to a formal commercial partnership. This collaboration involves the joint promotion of their products to researchers actively working on the development of liquid biopsy applications utilizing the Agena MassARRAY platform.

Company's Business Segments

• Genomics and Molecular Diagnostics : Genomics and Molecular Diagnostics segment includes Detecting, Monitoring Low-frequency Mutations, Gene Fusions, Copy Number Alterations (CNAs).